SCHEMBL15328221

SCHEMBL15328221

Cc1[nH]c(/C=C2\C(=O)Nc3cc(NC(=O)c4c[nH]cc(-c5ccc(F)cc5)c4=O)ccc32)c(C)c1CCC(=O)N1CCN(C)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 9/20 0.65
FLT3 P36888 7/20 0.65
KDR P35968 7/20 0.49
KIT P10721 2/20 0.49
FLT4 P35916 2/20 0.49
PDGFRB P09619 5/20 0.48
FGFR1 P11362 5/20 0.48
CHEK1 O14757 2/20 0.48
CSF1R P07333 2/20 0.48
ABL1 P00519 1/20 0.48
LCK P06239 1/20 0.48
FYN P06241 1/20 0.48
RET P07949 1/20 0.48
PHKG2 P15735 1/20 0.48
FLT1 P17948 1/20 0.48
FGFR3 P22607 1/20 0.48
AXL P30530 1/20 0.48
ABL2 P42684 1/20 0.48
PTK2 Q05397 1/20 0.48
KCNH2 Q12809 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15328223 1.00 AURKB (0.65) AURKBFLT3KDRKITFLT4
SCHEMBL15327867 0.93 AURKB (0.57) AURKBFLT3KDRKITFLT4
SCHEMBL15327864 0.93 AURKB (0.57) AURKBFLT3KDRKITFLT4
SCHEMBL15328166 0.89 KDR (0.61) AURKBFLT3KDRKITFLT4
SCHEMBL15328168 0.89 KDR (0.61) AURKBFLT3KDRKITFLT4
SCHEMBL15328182 0.89 FLT3 (0.63) AURKBFLT3KDRKITFLT4
SCHEMBL15328185 0.89 FLT3 (0.63) AURKBFLT3KDRKITFLT4
SCHEMBL15328187 0.87 AURKB (0.56) AURKBFLT3KDRKITFLT4
SCHEMBL15328188 0.87 AURKB (0.56) AURKBFLT3KDRKITFLT4
SCHEMBL15328095 0.85 FLT3 (0.64) AURKBFLT3KDRKITFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP claimed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 AURKB 100/4885FLT3 1086/4885KDR 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.